Personalis, Inc. Announces Collaboration With Merck KGaA, Darmstadt, Germany, to Identify & Develop Novel Biomarkers for Canc...
19 11월 2019 - 10:00PM
Business Wire
Personalis, Inc. (Nasdaq:PSNL), a leader in advanced genomics
for cancer, today announced a collaboration with Merck KGaA,
Darmstadt, Germany, a leading science and technology company, to
investigate novel biomarkers of response and mechanisms of
resistance to cancer therapies. Merck KGaA, Darmstadt, Germany,
will utilize Personalis’ newest cancer immunogenomics platform,
ImmunoID NeXT™, for clinical biomarker identification and
development.
ImmunoID NeXT, through innovative assays and analytics, provides
a comprehensive view of each cancer’s genomics and immune
microenvironment from a single, limited tumor sample. The platform
is an end-to-end solution built for precision oncology biomarker
discovery through to clinical applications, enabling simultaneous
analysis of cancer mutations, the immune repertoire, neoantigens,
tumor escape mechanisms, DNA repair pathways, human leukocyte
antigens (including typing, loss of heterozygosity, and somatic
mutation detection), tumor mutational burden (TMB), microsatellite
instability (MSI), oncoviruses, immune checkpoints, gene
expression, immune signatures, and other advanced biomarkers.
“Merck KGaA, Darmstadt, Germany, is a global leader in cancer
therapeutic development and we’re thrilled to collaborate with them
to identify the next generation of clinical biomarkers for cancer
therapies,” said Richard Chen, MD, CSO of Personalis. “We will work
with Merck KGaA, Darmstadt, Germany, to leverage the NeXT Platform
for novel biomarker identification, analysis of therapy resistance
mechanisms, patient stratification, combination therapy strategy,
and comprehensive molecular categorization of cancers for enabling
precision therapy.”
About Personalis, Inc.
Personalis, Inc. is a growing cancer genomics company
transforming the development of next-generation therapies by
providing more comprehensive molecular data about each patient’s
cancer and immune response. The company’s NeXT Platform is designed
to adapt to the complex and evolving understanding of cancer,
providing its biopharmaceutical customers with information on all
of the approximately 20,000 human genes, together with the immune
system, from a single tissue sample. The Personalis Clinical
Laboratory is GxP aligned as well as CLIA’88-certified and
CAP-accredited. For more information, please visit
www.personalis.com and follow Personalis on Twitter
(@PersonalisInc).
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, a leading science and technology
company, operates across healthcare, life science and performance
materials. Around 56,000 employees work to make a positive
difference to millions of people’s lives every day by creating more
joyful and sustainable ways to live. From advancing gene editing
technologies and discovering unique ways to treat the most
challenging diseases to enabling the intelligence of devices – the
company is everywhere. In 2018, Merck KGaA, Darmstadt, Germany,
generated sales of € 14.8 billion in 66 countries.
The company holds the global rights to the name and trademark
“Merck” internationally. The only exceptions are the United States
and Canada, where the business sectors of Merck KGaA, Darmstadt,
Germany, operate as EMD Serono in healthcare, MilliporeSigma in
life science, and EMD Performance Materials. Since its founding
1668, scientific exploration and responsible entrepreneurship have
been key to the company’s technological and scientific advances. To
this day, the founding family remains the majority owner of the
publicly listed company.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191119005366/en/
Investor Relations Contact for Personalis: Caroline
Corner investors@personalis.com www.westwicke.com 415-202-5678
Media Contact for Personalis: Jennifer Havlek
pr@personalis.com www.personalis.com 650-752-1300
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024